Nutriband Inc. (NASDAQ: NTRB) has received a Notice of Allowance from the U.S. Patent and Trademark Office for commercial brand name trademarks associated with its lead abuse-deterrent fentanyl transdermal system, a step that locks in naming rights as the company moves toward regulatory submissions and potential commercialization. The notice, dated Nov. 3, 2026, covers trademarks the company intends to register in the United States and internationally, and Nutriband is preparing to submit its proposed global brand name to the U.S. Food and Drug Administration, the European Medicines Agency and other regulatory authorities for preapproval review. The naming process emphasizes minimizing potential medication errors associated with similar-looking or similar-sounding drug names, a detail that matters in a category where confusion can carry serious safety consequences. The company’s lead product incorporates its proprietary AVERSA technology, designed to deter intentional abuse and misuse of fentanyl patches while reducing accidental exposure risks. Nutriband estimates potential peak annual U.S. sales of $80 million to $200 million for the product and is pursuing development for international markets. AVERSA uses aversive agents in transdermal patches to discourage misuse of medications with abuse potential, including opioids and stimulants, and is supported by patents issued in 46 countries. For investors, the allowance is a concrete milestone in the intellectual property pathway that underpins the company’s valuation case, even though it does not by itself constitute regulatory approval or a guarantee of commercial success. The company’s progress can be tracked through its newsroom at https://ibn.fm/NTRB, and the full press release is available at https://ibn.fm/FN3Or. Nutriband maintains a corporate website at www.nutriband.com. The announcement was distributed through BioMedWire, one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other communications services. Readers can review the publisher’s terms at https://www.BioMedWire.com/Disclaimer. The trademark allowance is important because it secures the brand identity that will accompany the product through FDA and EMA preapproval review, a process where name confusion is a recognized safety concern. It also comes as Nutriband positions AVERSA as a platform technology that can be incorporated into any transdermal patch to prevent abuse, misuse, diversion and accidental exposure of drugs with abuse potential. Whether that platform translates into the projected sales range will depend on clinical and regulatory outcomes, but the naming milestone reduces one layer of commercial uncertainty as the company prepares for broader regulatory engagement.
Nutriband's USPTO Allowance for Fentanyl Patch Brand Names Signals Progress Toward Market Launch
Nutriband Inc. received a USPTO Notice of Allowance for brand names tied to its abuse-deterrent fentanyl patch, advancing regulatory and commercial preparations for a product with peak U.S. sales projected at $80 million to $200 million.


